A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Molecular Medicine Bookmark and Share

Molecular Medicine

The Department of Molecular Medicine of Beckman Research Institute of City of Hope  advances translational medicine through breakthroughs in basic science using chemical biology and genomic approaches. Our investigators lead cutting-edge research to determine the mechanisms underlying cancer and other serious diseases such as diabetes. The goal of the department is to customize prevention and treatment of such illnesses by developing targeted therapies for an individual’s genomic profile. Success produces more effective clinical responses to our treatments and less drug toxicity and resistance.
 
The department is composed of a carefully crafted team of experts in chemistry, biology, biochemistry and biophysics that identifies new target molecules to treat cancer, creates personalized medicines from natural products, develops bioorganic approaches for cancer therapy, and evaluates genomic markers to predict cancer risk and response to therapy. By collaborating with multidisciplinary groups that include basic, translational and clinical researchers throughout City of Hope, we transform our key findings into novel therapies that improve the quality of life for patients everywhere.
 
The department has a robust pipeline of novel, molecularly targeted therapeutics that includes engineered antibodies and small molecules. To facilitate the translation of these and other clinical candidates, the department is home to the Chemical GMP Synthesis Facility (CGSF),   which is a 3000-square-foot, state-of-the-art manufacturing facility where our small and large molecule therapeutics are prepared for phase I and II clinical trials. The CGSF plays a key role in bridging basic science and translational medicine at City of Hope and allows for more efficient and cost-effective means to translate our science into clinical practice. We are able to bring promising new therapies to the patient faster and more effectively. 

To accomplish our mission, the Molecular Medicine team uses approaches and technologies that include:
 
  • sophisticated organic synthesis and medicinal chemistry
  • high-tech protein engineering
  • functional genomics, proteomics, and microarray gene expression profiling
  • high throughput screens of plant extracts and chemical libraries
  • advanced NMR spectroscopy and computational modeling
  • state-of-the-art X-ray crystallography
  • leading-edge super-resolution microscopy
 
These activities are supported by the Drug Discovery and Structural Biology (DDSB) Core, which is also housed in the department.
 
 
Laboratory Research
 
Jacob Berlin, Ph.D. - Molecular medicine
Dr. Berlin’s research group is focused on the application of nanomaterials for the diagnosis and treatment of cancer.
 
Yuan Chen, Ph.D. - Ubiquitin-like modifications
Dr. Chen investigates post-translational modifications by ubiquitin-like proteins via a wide range of techniques that include determination of protein structures and dynamics by NMR, investigation of enzyme mechanisms by biochemical and biophysical means, and examination of the role of these modifications in response to DNA damage by cellular and molecular biology methods.
 
David Horne, Ph.D., chair  - Synthetic/medicinal chemistry
Dr. Horne’s laboratory specializes in the synthesis of complex natural products and derivatives to develop molecularly targeted agents that are less toxic and more effective in treating the unmet needs in cancer and diabetes.
 
Robert Hickey, Ph.D. - Molecular Medicine
 
Tijana Jovanovic-Talisman, Ph.D. - Super-resolution microscopy
Dr. Jovanovic-Talisman’s research group employs novel, quantitative imaging techniques and nano-biological assays to investigate biological mechanisms and advance therapeutics.

Theodore G. Krontiris, M.D., Ph.D. - Genetic risk and disease
Dr. Krontiris and his group examine the relationship between certain unstable regions of the genome, known as hypervariable minisatellites, and cancer risk.

John Termini, Ph.D. - Molecular medicine
Members of Dr. Termini's laboratory are interested in understanding the role of DNA adducts in cancer. This encompasses mechanisms of formation, structure elucidation of novel adducts, quantitative determination in vivo, functional implications, and removal/repair.

John Williams, Ph.D. - X-ray crystallography
Dr. Williams specializes in the use of X-ray crystallography to study protein-protein and drug-protein interactions for the design of novel therapeutic agents for the treatment of cancer.
 

Molecular Medicine Faculty

Molecular Medicine

Molecular Medicine

The Department of Molecular Medicine of Beckman Research Institute of City of Hope  advances translational medicine through breakthroughs in basic science using chemical biology and genomic approaches. Our investigators lead cutting-edge research to determine the mechanisms underlying cancer and other serious diseases such as diabetes. The goal of the department is to customize prevention and treatment of such illnesses by developing targeted therapies for an individual’s genomic profile. Success produces more effective clinical responses to our treatments and less drug toxicity and resistance.
 
The department is composed of a carefully crafted team of experts in chemistry, biology, biochemistry and biophysics that identifies new target molecules to treat cancer, creates personalized medicines from natural products, develops bioorganic approaches for cancer therapy, and evaluates genomic markers to predict cancer risk and response to therapy. By collaborating with multidisciplinary groups that include basic, translational and clinical researchers throughout City of Hope, we transform our key findings into novel therapies that improve the quality of life for patients everywhere.
 
The department has a robust pipeline of novel, molecularly targeted therapeutics that includes engineered antibodies and small molecules. To facilitate the translation of these and other clinical candidates, the department is home to the Chemical GMP Synthesis Facility (CGSF),   which is a 3000-square-foot, state-of-the-art manufacturing facility where our small and large molecule therapeutics are prepared for phase I and II clinical trials. The CGSF plays a key role in bridging basic science and translational medicine at City of Hope and allows for more efficient and cost-effective means to translate our science into clinical practice. We are able to bring promising new therapies to the patient faster and more effectively. 

To accomplish our mission, the Molecular Medicine team uses approaches and technologies that include:
 
  • sophisticated organic synthesis and medicinal chemistry
  • high-tech protein engineering
  • functional genomics, proteomics, and microarray gene expression profiling
  • high throughput screens of plant extracts and chemical libraries
  • advanced NMR spectroscopy and computational modeling
  • state-of-the-art X-ray crystallography
  • leading-edge super-resolution microscopy
 
These activities are supported by the Drug Discovery and Structural Biology (DDSB) Core, which is also housed in the department.
 
 
Laboratory Research
 
Jacob Berlin, Ph.D. - Molecular medicine
Dr. Berlin’s research group is focused on the application of nanomaterials for the diagnosis and treatment of cancer.
 
Yuan Chen, Ph.D. - Ubiquitin-like modifications
Dr. Chen investigates post-translational modifications by ubiquitin-like proteins via a wide range of techniques that include determination of protein structures and dynamics by NMR, investigation of enzyme mechanisms by biochemical and biophysical means, and examination of the role of these modifications in response to DNA damage by cellular and molecular biology methods.
 
David Horne, Ph.D., chair  - Synthetic/medicinal chemistry
Dr. Horne’s laboratory specializes in the synthesis of complex natural products and derivatives to develop molecularly targeted agents that are less toxic and more effective in treating the unmet needs in cancer and diabetes.
 
Robert Hickey, Ph.D. - Molecular Medicine
 
Tijana Jovanovic-Talisman, Ph.D. - Super-resolution microscopy
Dr. Jovanovic-Talisman’s research group employs novel, quantitative imaging techniques and nano-biological assays to investigate biological mechanisms and advance therapeutics.

Theodore G. Krontiris, M.D., Ph.D. - Genetic risk and disease
Dr. Krontiris and his group examine the relationship between certain unstable regions of the genome, known as hypervariable minisatellites, and cancer risk.

John Termini, Ph.D. - Molecular medicine
Members of Dr. Termini's laboratory are interested in understanding the role of DNA adducts in cancer. This encompasses mechanisms of formation, structure elucidation of novel adducts, quantitative determination in vivo, functional implications, and removal/repair.

John Williams, Ph.D. - X-ray crystallography
Dr. Williams specializes in the use of X-ray crystallography to study protein-protein and drug-protein interactions for the design of novel therapeutic agents for the treatment of cancer.
 

Molecular Medicine Faculty

Molecular Medicine Faculty

Overview
Beckman Research Institute of City of Hope is responsible for fundamentally expanding the world’s understanding of how biology affects diseases such as cancer, HIV/AIDS and diabetes.
 
 
Research Departments/Divisions

City of Hope is a leader in translational research - integrating basic science, clinical research and patient care.
 

Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 

Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

City of Hope’s Irell & Manella Graduate School of Biological Sciences equips students with the skills and strategies to transform the future of modern medicine.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 


NEWS & UPDATES
  • The physical side effects of cancer can damage anyone’s self-confidence, but especially that of women who, rightly or wrongly, are more likely to find their appearance (or their own perception of their appearance) directly connected to their ability to face the world with something resembling ap...
  • The promise of stem cell therapy has long been studied in laboratories. Now, as medicine enters an era in which this therapy will be increasingly available to patients, the nurses who help deliver it will be in the spotlight. City of Hope, which has launched its Alpha Clinic for Cell Therapy and Innovation (ACT...
  • Just because you can treat a condition, such as high cholesterol, at the end of life — well, that doesn’t mean you should. That’s the basic lesson of a study to be published March 30 in JAMA Internal Medicine. The ramifications go far beyond that. The research, in which City of Hope’s Betty Fe...
  • The understanding of the relationship between genetics and cancer risk continues to grow, with more genetic testing than ever before available to patients. However, the adage that a little knowledge is a dangerous thing is applicable: Without context for what a test result means, and without meaningful guidance...
  • Standard prostate biopsies haven’t changed significantly in the past 30 years – nor have the problems inherent with them. Regular biopsies have an expected error rate: Tumors may potentially be undersampled and, 30 percent of the time, men who undergo a radical prostatectomy are found to have more aggress...
  • In the field of cancer, patients have had surgery, chemotherapy and radiation therapy as options. Now, as City of Hope officially opens the Alpha Clinic for Cellular Therapy and Innovation, patients battling cancer and other life-threatening diseases have another option: stem-cell-based therapy. The Alpha Clini...
  • How does the environment affect our health? Specifically, how does it affect our risk of cancer? City of Hope physicians and researchers recently answered those questions in an Ask the Experts event in Corona, California, explaining the underlying facts about how the environment can affect our health. Moderator...
  • Nurses and other medical professionals have come to understand that it’s not enough just to fight disease. They also must provide pain relief, symptom control, and an unrelenting commitment to improve patients’ quality of life — especially at the end of life. Not too long ago, this was a relatively ...
  • “Tonight, I’m launching a new precision medicine initiative to bring us closer to curing diseases like cancer.” These were the words of President Barack Obama on Jan. 20, 2015, during his State of the Union address. So what is precision medicine, and how close are we to making it a reality for...
  • March is Colon Cancer Awareness Month. How sad, yet how serendipitous, that the co-creator of “The Simpsons” Sam Simon passed away in March after a four-year battle against colon cancer. What message can we all learn from his illness that can help us prevent and overcome colon cancer in our own lives? Colon can...
  • Misagh Karimi, M.D., assistant clinical professor, is a medical oncologist at one of City of Hope’s newest community practice locations, located in Corona in Riverside County. A recent community health report from Corona’s public health department stated that obesity rates for teens and adults in Riverside Coun...
  • In 1975, the median survival for patients with ovarian cancer was about 12 months. Today, the median survival is more than 5 years. Although researchers and clinicians are far from satisfied, the progress in ovarian cancer treatment is encouraging, said Robert Morgan, M.D., F.A.C.P., professor of medical oncolo...
  • Colorectal cancer may be one of the most common cancers in both men and women, but it’s also one of the most curable cancers. Today, because of effective screening tests and more advanced treatment options, there are more than 1 million survivors of colorectal cancer in the United States. Here, colorectal...
  • Breast cancer treatment can damage a woman’s ability to become pregnant, making the impact on fertility one of the key factors that many consider when choosing a therapy regimen. Now a study has found that breast cancer patients treated with a hormone-blocking drug in addition to chemotherapy were less li...
  • My colleagues in the clinic know I’ve got a soft spot. Last week, a patient of mine offered me a fantastic compliment. “You’re looking younger these days, Dr. Pal!” she said, offering me a big hug as she proceeded out of the clinic room. Lovely, I thought. The early morning workouts are paying off. She continue...